Glioma Market
Key Highlights
- As per the American Brain Tumor Association, more than 79,000 new cases of brain tumors are diagnosed each year; but only about 23,880 of these are malignant (cancerous) tumors or high-grade glioma of the brain or spinal cord. Gliomas overall make up about 74% of malignant brain tumors, wherein men are at a slightly higher risk, and the incidence of malignant brain tumors is low. In addition, anaplastic astrocytoma occurs more often in younger adults ages 30–50, accounting for 17% of primary malignant brain tumors. Only 9% of childhood brain tumors are GBMs.
- Glioma epidemiology is segmented as Total Incident Population of Glioma, Grade-specific Incident Population of Glioma, Type-specific Population of High-grade Glioma (including Diffuse Midline Glioma, Glioblastoma, and others), Type-specific Population of Low-grade Glioma (including Diffuse astrocytoma, Pilocytic Astrocytoma, and others), Age-specific Population of Glioma, and Glioma Cases Based on Molecular Alterations] in the Glioma market report.
Request for unlocking CAGR of Glioma Market
DelveInsight’s “Glioma– Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Glioma, historical and forecasted epidemiology as well as the Glioma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Glioma market report provides current treatment practices, emerging drugs, Glioma market share of the individual therapies, and current and forecasted Glioma market size from 2019 to 2032, segmented by seven major markets. The report also covers current Glioma treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the United Kingdom
- Japan
Study period: 2019–2032
Glioma Market Disease: Understanding and Treatment Algorithm
The DelveInsight’s Glioma market report gives a thorough understanding of Glioma by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. A glioma is a tumor of the central nervous system that arises from glial stem or progenitor cells. Glial cells are a type of cell widely present in the nervous system. Gliomas mostly occur in the brain and, rarely, in the spinal cord. Classification of gliomas is complex and based partly on the microscopic appearance of the tumor (histologic classification) and partly on the gene changes (mutations) that are implicated in tumor development. Differentiation is an important concept for the histologic classification of gliomas and refers to the “specialization” of the cell. Gliomas can have four different grades of differentiation. Grade 1 gliomas show the highest level of differentiation and are the least malignant, while grade 4 tumors are the least differentiated and most malignant. Loss of differentiation is known as anaplasia, hence the name of several grade 3 gliomas. Grade 1 and grade 2 gliomas are often referred to as low-grade gliomas, while grade 3 and 4 are referred to as malignant gliomas. Further classification is possible depending on the genetic alterations that occurred in the affected cells. Gliomas are caused by the accumulation of genetic mutations in glial stem or progenitor cells, leading to their uncontrolled growth. Mutated genes are typically involved in functions such as tumor suppression, DNA repair, and regulation of cell growth.
Developing gliomas can compress areas of the brain where they occur and cause various symptoms including headaches, nausea, vomiting, cognitive impairment, seizures, gait imbalance, language impairment (aphasia), numbness or weakness of one side of the body (hemiparesis), visual changes, and personality changes.
Glioma Diagnosis
A diagnosis of glioma requires an extensive patient history, as well as a complete physical and neurological examination. The presence of a brain tumor can be suspected with medical imaging. Magnetic resonance imaging (MRI) is the imaging modality of choice for initial evaluation of glioma. The final diagnosis, and therefore plan for treatment, can only be determined after a piece of tumor tissue is analyzed microscopically. Further characterization can be done by testing the DNA of the affected cells to determine if mutations in genes associated with certain subtypes of glioma are present.
Glioma Treatment
The treatment of gliomas often requires a combination of neurosurgical interventions, radiation therapy, and chemotherapy. In addition to chemotherapy, medication prescribed to individuals with gliomas might include anti-epileptic medication (if the patient has seizures), anti-coagulation medication (if blood clots develop), and corticosteroids, to alleviate neurological symptoms caused by the accumulation of fluid around the tumor (peritumoral edema).
Glioma Epidemiology
The Glioma epidemiology section provides insights into historical and current Glioma patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Glioma report also provides the diagnosed patient pool, their trends and assumptions undertaken.
Key findings
- As per the American Brain Tumor Association, more than 79,000 new cases of brain tumors are diagnosed each year; but only about 23,880 of these are malignant (cancerous) tumors or high-grade glioma of the brain or spinal cord. Gliomas overall make up about 74% of malignant brain tumors, wherein men are at a slightly higher risk, and the incidence of malignant brain tumors is low. In addition, anaplastic astrocytoma occurs more often in younger adults ages 30–50, accounting for 17% of primary malignant brain tumors. Only 9% of childhood brain tumors are GBMs.
- The Glioma epidemiology covered in the report provides historical as well as forecasted Glioma epidemiology [segmented as Total Incident Population of Glioma, Grade-specific Incident Population of Glioma, Type-specific Population of High-grade Glioma (including Diffuse Midline Glioma, Glioblastoma, and others), Type-specific Population of Low-grade Glioma (including Diffuse astrocytoma, Pilocytic Astrocytoma, and others), Age-specific Population of Glioma, and Glioma Cases Based on Molecular Alterations] in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.
Country-wise Glioma Epidemiology
The epidemiology segment also provides the Glioma epidemiology data and findings across the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Learn more about the evolving epidemiology trends and key developments: Glioma Epidemiology Forecast
Glioma Drug Chapters
The drug chapter segment of the Glioma report encloses the detailed analysis of Glioma marketed drugs and late-stage (Phase III and Phase II) Glioma pipeline drugs. It also helps understand the Glioma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Glioma drugs
The report details the emerging Glioma therapies under the late and mid-stage of development for Glioma treatment.
Glioma Market Outlook
The Glioma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Glioma market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
This segment gives a thorough detail of the Glioma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Glioma market in 7MM is expected to witness a major change in the study period 2019–2032.
Key findings
This section includes a glimpse of the Glioma market in 7MM.
The United States: Glioma Market Outlook
This section provides the total Glioma market size and market size by therapies in the United States.
EU4 and the United Kingdom Countries: Glioma Market Outlook
The total Glioma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan: Glioma Market Outlook
The total Glioma market size and market size by therapies in Japan is also mentioned.
|
Report Metrics |
Details |
|
Study Period |
2019 to 2032 |
|
Base Year |
2021 |
|
Forecast Period |
2022 to 2032 |
|
CAGR |
|
|
Glioma Drugs |
ONC 201, DSP-7888, AV-GBM-1, DB102, AB-218, and Others. |
|
Key Companies |
Chimerix, Sumitomo Dainippon Pharma, AIVITA Biomedical, Denovo Biopharma, AnHeart Therapeutics, Plus Therapeutics, Basilea Pharmaceutica, BeiGene, Kazia Therapeutics, AstraZeneca, Nerviano Medical Sciences, VBL Therapeutics, Philogen S.p.A., Xennials Therapeutics, Laminar Pharmaceutical, and Many Others. |
Glioma Drug Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Glioma market or expected to get launched in the market during the study period 2019–2032. The analysis covers Glioma market uptake by drugs, patient uptake by therapies, and sales of each drug.
This will help in understanding the Glioma drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
Glioma Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Glioma’s key players involved in developing targeted therapeutics.
Glioma Clinical Trial Development Activities
The Glioma clinical trial report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Glioma emerging therapies.
Learn more about emerging therapies and key companies: Glioma Pipeline Insight
Glioma Reimbursement Scenario
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL Views
To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Glioma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Glioma market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform competitive and market intelligence analysis of the Glioma market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Glioma Market Report
- Descriptive overview of Glioma, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
- Comprehensive insight into the Glioma epidemiology and forecasts in the 7MM
- An all-inclusive account of both the current and emerging therapies for Glioma, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
- Exhaustive analysis of the Glioma market; historical and forecasted covering drug outreach in the 7MM
- Detailed Patient Based Market Forecasting determines the trends shaping and driving the global Glioma market
Glioma Market Report Highlights
- In the coming years, the Glioma market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Glioma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing Glioma therapies. The launch of emerging therapies will significantly impact the Glioma market
- A better understanding of Glioma pathogenesis will also contribute to the development of novel therapeutics for Glioma
- Our in-depth analysis of the Glioma pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed Glioma clinical trial profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Glioma Report Insights
- Patient-Based Market Forecasting
- Therapeutic approaches
- Glioma pipeline analysis
- Glioma market size and trends
- Glioma market opportunities
- Impact of upcoming therapies
Glioma Report Key Strengths
- 11 years’ forecast
- 7MM coverage
- Glioma epidemiology segmentation
- Key cross competition
- KOL views
- Glioma drugs uptake
Glioma Report Assessment
- Current treatment practices
- Unmet needs
- Glioma pipeline product profiles
- Glioma market attractiveness
Key Questions
Glioma market insights:
- What would be the Glioma market growth till 2032, and what will be the resultant market size in 2032?
- What was the Glioma drug class share (in percentage) distribution in 2019, and how would it look in 2032?
- What would be the Glioma total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
- What are the key findings of the market across 7MM, and which country will have the largest Glioma market size during the forecast period (2019–2032)
- How would the unmet needs affect the Glioma market dynamics and subsequent analysis of the associated trends?
Glioma Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Glioma?
- What is the historical and forecasted Glioma patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
- What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current treatment guidelines and treatment options, in addition to approved therapies for Glioma in the US, Europe, and Japan?
- What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Glioma therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Glioma and its status, along with the challenges faced?
Reasons to Buy
- The Patient Based Market Forecasting analysis will help in developing business strategies by understanding trends shaping and driving the Glioma market
- Organize sales and marketing efforts by identifying the best opportunities for Glioma in the US, Europe (Germany, France, Italy, and Spain) and the United Kingdom, and Japan
- Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors
Frequently Asked Questions
1. Key Insights
2. Executive Summary of Glioma
3. Competitive Intelligence Analysis for Glioma
4. Glioma: Market Overview at a Glance
4.1. Glioma Total Market Share (%) Distribution in 2019
4.2. Glioma Total Market Share (%) Distribution in 2032
5. Glioma: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Glioma Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Glioma Epidemiology Scenario in the 7MM (2019-2032)
7.4. United States Epidemiology
7.4.1. Glioma Epidemiology Scenario in the United States (2019-2032)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Glioma Epidemiology Scenario in Germany (2019-2032)
7.5.2. France Epidemiology
7.5.2.1. Glioma Epidemiology Scenario in France (2019-2032)
7.5.3. Italy Epidemiology
7.5.3.1. Glioma Epidemiology Scenario in Italy (2019-2032)
7.5.4. Spain Epidemiology
7.5.4.1. Glioma Epidemiology Scenario in Spain (2019-2032)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Glioma Epidemiology Scenario in the United Kingdom (2019-2032)
7.5.6. Japan Epidemiology
7.5.6.1. Glioma Epidemiology Scenario in Japan (2019-2032)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Glioma Treatment and Management
8.2. Glioma Treatment Algorithm
9. Glioma Unmet Needs
10. Key Endpoints of Glioma Treatment
11. Glioma Marketed Products
11.1. List of Glioma Marketed Drugs in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Glioma Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Glioma: Seven Major Market Analysis
13.1. Key Findings
13.2. Glioma Market Size in 7MM
13.3. Glioma Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Glioma Total Market Size in the United States
15.1.2. Glioma Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Glioma Total Market Size in Germany
15.3.2. Glioma Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Glioma Total Market Size in France
15.4.2. Glioma Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Glioma Total Market Size in Italy
15.5.2. Glioma Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Glioma Total Market Size in Spain
15.6.2. Glioma Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Glioma Total Market Size in the United Kingdom
15.7.2. Glioma Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Glioma Total Market Size in Japan
15.8.3. Glioma Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Glioma
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
*The table of contents is not exhaustive; the final content may vary.
List of Table
Table 1: 7MM Glioma Epidemiology (2019-2032)
Table 2: 7MM Glioma Diagnosed and Treatable Cases (2019-2032)
Table 3: Glioma Epidemiology in the United States (2019-2032)
Table 4: Glioma Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Glioma Epidemiology in Germany (2019-2032)
Table 6: Glioma Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Glioma Epidemiology in France (2019-2032)
Table 8: Glioma Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Glioma Epidemiology in Italy (2019-2032)
Table 10: Glioma Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Glioma Epidemiology in Spain (2019-2032)
Table 12: Glioma Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Glioma Epidemiology in the UK (2019-2032)
Table 14: Glioma Diagnosed and Treatable Cases in the UK (2019-2032)
Table 15: Glioma Epidemiology in Japan (2019-2032)
Table 16: Glioma Diagnosed and Treatable Cases in Japan (2019-2032)
Table 17: Drug Name, Clinical Trials by Recruitment status
Table 18: Drug Name, Clinical Trials by Zone
Table 19: Total Seven Major Market Size in USD, Million (2019-2032)
Table 20: Region-wise Market Size in USD, Million (2019-2032)
Table 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Table 22: United States Market Size in USD, Million (2019-2032)
Table 23: United States Market Size by Therapy in USD, Million (2019-2032)
Table 24: Germany Market Size in USD, Million (2019-2032)
Table 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Table 26: France Market Size in USD, Million (2019-2032)
Table 27: France Market Size by Therapy in USD, Million (2019-2032)
Table 28: Italy Market Size in USD, Million (2019-2032)
Table 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Table 30: Spain Market Size in USD, Million (2019-2032)
Table 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Table 32: United Kingdom Market Size in USD, Million (2019-2032)
Table 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Table 34: Japan Market Size in USD, Million (2019-2032)
Table 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of tables is not exhaustive; the final content may vary
List of Figures
Figure 1: 7MM Glioma Epidemiology (2019-2032)
Figure 2: 7MM Glioma Diagnosed and Treatable Cases (2019-2032)
Figure 3: Glioma Epidemiology in the United States (2019-2032)
Figure 4: Glioma Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5: Glioma Epidemiology in Germany (2019-2032)
Figure 6: Glioma Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7: Glioma Epidemiology in France (2019-2032)
Figure 8: Glioma Diagnosed and Treatable Cases in France (2019-2032)
Figure 9: Glioma Epidemiology in Italy (2019-2032)
Figure 10: Glioma Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11: Glioma Epidemiology in Spain (2019-2032)
Figure 12: Glioma Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13: Glioma Epidemiology in the UK (2019-2032)
Figure 14: Glioma Diagnosed and Treatable Cases in the UK (2019-2032)
Figure 15: Glioma Epidemiology in Japan (2019-2032)
Figure 16: Glioma Diagnosed and Treatable Cases in Japan (2019-2032)
Figure 17: Drug Name, Clinical Trials by Recruitment status
Figure 18: Drug Name, Clinical Trials by Zone
Figure 19: Total Seven Major Market Size in USD, Million (2019-2032)
Figure 20: Region-wise Market Size in USD, Million (2019-2032)
Figure 21: 7MM-Market Size by Therapy in USD, Million (2019-2032)
Figure 22: United States Market Size in USD, Million (2019-2032)
Figure 23: United States Market Size by Therapy in USD, Million (2019-2032)
Figure 24: Germany Market Size in USD, Million (2019-2032)
Figure 25: Germany Market Size by Therapy in USD, Million (2019-2032)
Figure 26: France Market Size in USD, Million (2019-2032)
Figure 27: France Market Size by Therapy in USD, Million (2019-2032)
Figure 28: Italy Market Size in USD, Million (2019-2032)
Figure 29: Italy Market Size by Therapy in USD, Million (2019-2032)
Figure 30: Spain Market Size in USD, Million (2019-2032)
Figure 31: Spain Market Size by Therapy in USD, Million (2019-2032)
Figure 32: United Kingdom Market Size in USD, Million (2019-2032)
Figure 33: United Kingdom Market Size by Therapy in USD, Million (2019-2032)
Figure 34: Japan Market Size in USD, Million (2019-2032)
Figure 35: Japan Market Size by Therapy in USD, Million (2019-2032)
*The list of figures is not exhaustive; the final content may vary